Fred Aslan describes how Artiva is harnessing the ability of NK cells to act as a modulator of antibody dependent cellular cytotoxicity as a therapeutic property of its cell therapies.
Watch the interview here.
Inside Precision Medicine spoke with Artiva’s Chief Medical Officer, Dr. Subhashis Banerjee, about our clinical development approach for AlloNK® in autoimmune disease. In the Q&A, Dr. Banerjee outlines how we are advancing AlloNK® through a parallel trial strategy, conducting both a Phase 2a basket trial and an investigator-initiated study in the community setting. These trials...
In this interview with Pharmaceutical Manufacturer, Artiva CEO Fred Aslan, M.D., discusses the unique advantages of natural killer (NK) cell therapies and the company’s mission to bring scalable, off-the-shelf treatments to patients with autoimmune diseases. The Q&A explores how Artiva’s AlloNK® platform—comprising non-genetically modified, cryopreserved NK cells combined with disease-targeting monoclonal antibodies—could offer a more...
In a new feature published by GEN (Genetic Engineering & Biotechnology News), natural killer (NK) cells are in the spotlight showcasing their potential as the next generation of immunotherapies. This article explores how scientific and technological advances are helping cell therapy developers harness NK cells to expand the reach of cell therapy beyond oncology and...